Crown Bioscience Inc.
CrownBio's Integrated Oncology Platform Helps Advance Apogenix's Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer
The data derived from studies using CrownBio's portfolio were first presented by Apogenix in an oral presentation at the AACR 2017 Annual Meeting . These data showed the immunotherapy's potential clinical utility and demonstrated the benefits of using CrownBio's platform in preclinical efficacy testing.
"CrownBio's integrated oncology platform confirmed our agent's efficacy in NSCLC and head and neck cancers," said Dr. Mauricio Redondo Müller, Director, Preclinical Development at Apogenix. "The scientific expertise, predictive tools, and well-validated models CrownBio provides gave us the data we needed to progress our HERA-GITRL immunotherapy to the next stage."
"It is our mission to deliver innovative technologies so that companies like Apogenix can leverage and accelerate their research," said Laurie Heilmann, SVP of Global Strategy, Marketing & Business Development. "Our scientific oncology platform uniquely enhances preclinical immunotherapy development and will continue to deliver valuable insights that drive new discoveries in this area."
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 100 million euros in financing rounds, public grants, and upfront payments from licensing agreements. The company is based in Heidelberg, Germany.
Crown Bioscience Inc. firstname.lastname@example.org
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
ThalesNano Inc.17.8.2018 11:01 | pressemeddelelse
ThalesNano Energy Introduces H-Genie™: Revolutionary Compact, High Pressure Hydrogen Gas Generation Platform for Chemists
Bombardier Inc.15.8.2018 22:49 | pressemeddelelse
Bombardier Establishes Automatic Securities Disposition Plan
Cisco15.8.2018 22:06 | pressemeddelelse
Cisco Reports Fourth Quarter and Fiscal Year 2018 Earnings
Open Society Foundations15.8.2018 17:23 | pressemeddelelse
Open Society Names New Head of West Africa Foundation
SharesPost15.8.2018 15:01 | pressemeddelelse
Huobi Joins GLASS Network and Invests in SharesPost
Corel14.8.2018 15:12 | pressemeddelelse
Pinnacle Studio 22 Ultimate Amps Up Video Editing with New Pro-inspired Features
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum